Bioventus Inc. (NASDAQ: BVS) reported fourth‑quarter 2025 results that surpassed analyst expectations, with worldwide revenue of $157.9 million, a 10.0 % increase from the $142.8 million reported a year earlier. Net income attributable to Bioventus rose to $14.8 million from a $0.4 million loss, while adjusted EBITDA climbed to $36.7 million, up 30 % from $28.3 million in the prior year quarter. Adjusted earnings per share were $0.24, a slight decline from $0.26 a year earlier but still above the consensus estimate of $0.22, representing a beat of $0.02 per share.
The revenue growth was driven by strong performance in the company’s core segments. Pain Treatments revenue increased 15.1 % to $79.7 million, led by robust sales of hyaluronic acid therapies for knee osteoarthritis. Surgical Solutions revenue grew 3.4 % to $55.5 million, supported by higher U.S. demand for bone graft substitutes. Restorative Therapies revenue rose 10.3 % on an organic basis to $22.7 million, a gain that was partially offset by the divestiture of the Advanced Rehabilitation Business at the end of 2024.
Margin expansion was a key highlight, with adjusted EBITDA margin reaching 23 %—an increase of 490 basis points from the 18 % margin reported a year earlier. The lift was driven by higher revenue, improved gross margin, and disciplined spending, allowing the company to maintain profitability despite the one‑time tax expense that reduced EPS slightly. Operating cash flow surged 97 % to $38.0 million, underscoring the company’s ability to convert sales into cash.
Bioventus reaffirmed its full‑year 2026 outlook, projecting net sales of $600 million to $610 million and adjusted EPS of $0.73 to $0.77. The guidance is slightly below consensus estimates, but management expressed confidence in sustaining growth and margin expansion. The company highlighted the full commercial launch of its peripheral nerve stimulation products, StimTrial and TalisMann, as a new revenue driver in the chronic pain market, and noted a targeted growth plan for its international business, which it believes will become a key growth engine in 2026.
Rob Claypoole, President and CEO, said, "Our team delivered strong fourth quarter performance, concluding an important year in which we strengthened our portfolio, drove above‑market growth, improved margins, and strengthened our balance sheet." He added, "These results reflect continued demand for our market‑leading therapies, and disciplined execution across our commercial and operational initiatives. We are entering 2026 from a position of strength and plan to invest to further accelerate our growth while expanding profitability and generating meaningful cash flow. We believe this is a powerful combination that positions Bioventus to deliver increased shareholder value." Claypoole also noted, "I recently attended our international sales meeting and came away even more confident that our international business is well positioned to become a key growth driver for Bioventus Inc. We now have a targeted growth plan, new structure and capabilities, and a highly energetic team that is very focused on driving excellent execution in 2026."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.